Prochymal- 8 Million cells/kg not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “8 million hMSCs/kg actual body weight IV on study Days 1 and 4”In the company’s words, NCT00136903 on ClinicalTrials.gov
- Tested for
- Graft Vs Host Disease
- Main trialPhase 2
- “To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.”In the company’s words, NCT00136903 on ClinicalTrials.gov
- Other names
- Remestemcel-L · hMSCs
Other drugs for Graft Vs Host Disease
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- AxatilimabIncyte · Syndax Pharmaceuticals · Phase 3
- DFL24498Dompé Farmaceutici S.p.A · Phase 3
- RovadicitinibChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Remestemcel-LMesoblast, Inc. · Phase 3
- RhPRG4Lubris Bio Pty Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 28 Jul 2006 | Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026